Crescendo Biologics to present at the 2024 AACR Annual Meeting
Press Releases
29 February 2024
Crescendo Biologics to participate in upcoming investor and partnering conferences
09 February 2024
Crescendo Biologics announces publication in Neoplasia of preclinical tumour penetration data supporting CB307
06 December 2023
Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC
24 October 2023
Crescendo Biologics to participate in upcoming investor and partnering conferences
04 September 2023
Crescendo Biologics wins significant European Patent Office ruling related to the engineering of immunoglobulin technology
24 July 2023
Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours
15 March 2023
Crescendo Biologics announces presentation at AACR 2023
31 January 2023
Crescendo Biologics is category winner for Biopharma and Vaccines
in 2023 UK DIT Life Sciences Innovator Showcase
24 January 2023
Crescendo Biologics to participate in upcoming investor conferences
20 October 2022
Crescendo Biologics to participate in upcoming investor conferences
10 October 2022
Crescendo Biologics’ CEO shortlisted for ‘Private Company CEO of the Year’ at the 2022 European Lifestars Awards
13 September 2022
Crescendo Biologics shortlisted for ‘Most Impactful UK Deal’ at 2022 OBN Awards
06 July 2022
Crescendo Biologics announces nomination of second proprietary clinical candidate from immuno-oncology Humabody VH development portfolio
14 June 2022
Crescendo Biologics to participate in upcoming investor conferences
04 May 2022
Crescendo Biologics to participate in upcoming conferences
09 March 2022
Crescendo Biologics announces presentations at AACR 2022
03 February 2022
Crescendo Biologics to participate in upcoming investor conferences
10 January 2022
BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies
31 December 2021
Crescendo Biologics announces publication of data for CB213, a PD-1xLAG-3 multi-specific Humabody®, in the British Journal of Cancer
16 December 2021
Crescendo to attend upcoming investor conferences
26 November 2021
Crescendo Biologics wins “Best Established Biotech Company” at the 2021 OBN Awards
21 October 2021
20 October 2021
16 September 2021
07 July 2021
Crescendo to participate in upcoming investor conferences
01 June 2021
20 May 2021
10 May 2021
27 April 2021
19 April 2021
16 April 2021
10 December 2020
Crescendo Biologics expands its ongoing collaboration with Takeda View PDF
06 July 2020
05 May 2020
03 February 2020
15 January 2020
25 October 2019
16 October 2019
Crescendo Biologics presenting at key industry events during October 2019
24 September 2019
12 September 2019
05 September 2019
23 July 2019
24 June 2019
31 May 2019
Crescendo Biologics announces prestigious academic research collaborationsView PDF